<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841512</url>
  </required_header>
  <id_info>
    <org_study_id>XT-150-1-0301</org_study_id>
    <nct_id>NCT04841512</nct_id>
  </id_info>
  <brief_title>Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis</brief_title>
  <official_title>A Placebo-controlled, Double-blind Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Facet Joint Osteoarthritis Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xalud Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xalud Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary safety and efficacy of XT-150 in the synovial capsule of osteoarthritic facet&#xD;
      joints in the vertebra of the spine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, safety and efficacy study of XT-150 in adult participants experiencing&#xD;
      back pain due to inflammation of the facet joint osteoarthritis (FJOA) and who are eligible&#xD;
      for intra-synovial glucocorticoid injection, or radiofrequency ablation of medial branches of&#xD;
      the primary dorsal ramus of the exiting nerve root, which innervates the adjacent facet&#xD;
      joints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Unblinded pharmacy, blinded clinical staff for administration and assessments</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog scale (VAS)</measure>
    <time_frame>6 months</time_frame>
    <description>0 - 100, 100 worst possible pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>6 months</time_frame>
    <description>10 dimensions, 0 - 5 score in each, with 5 as worst score in a dimension</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteoarthritis, Spine</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile phosphate-buffered saline for injection Single 1mL injection into the facet joint</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XT-150 Dose #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lower dose of XT-150 sterile solution for injection Single 1 mL injection into the facet joint</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XT-150 Dose #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Higher dose of XT-150 sterile solution for injection Single 1 mL injection into the facet joint</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XT-150</intervention_name>
    <description>non-viral Plasmid DNA encoding an IL-10 variant transgene</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>XT-150 Dose #1</arm_group_label>
    <arm_group_label>XT-150 Dose #2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, between 18 and 90 years of age, inclusive.&#xD;
&#xD;
          2. Sufficiently severe facet arthropathy (OA) of lumbar facets as determined by imaging,&#xD;
             eg. CT or MRI, to establish an underlying basis of disease, as determined by usual&#xD;
             bony and ligamentous signs of OA.&#xD;
&#xD;
          3. Complaint of nociceptive, mechanical pain of lumbar spine, in particular pain&#xD;
             localized to paramedian axis as opposed to midline or radicular. Radicular pain as a&#xD;
             secondary finding may be allowed if it is addition to mechanical pain and can be&#xD;
             clinically distinguished by subject&#xD;
&#xD;
          4. Low Back Pain (LBP) worsened by activity or motion of region&#xD;
&#xD;
          5. Have had a positive diagnostic facet pain block with lignocaine; admittance if subject&#xD;
             gains 50% relief of pain within 30 minutes of test injection&#xD;
&#xD;
          6. Be free of local or intra-articular infection, tumor or other causes of localized LBP,&#xD;
             for example Including spondylolysis/pars defect, and adjacent vertebral body&#xD;
             compression fracture based on MRI evaluation.&#xD;
&#xD;
          7. Symptomatic disease because of osteoarthritis, established by imaging of facet joint&#xD;
             and defined as a worst pain of at least 40 at any time during the preceding week&#xD;
             (based on scale of 0 to 100, with 100 representing &quot;pain as bad as you can imagine&quot;)&#xD;
             using Visual Analog Scale (VAS).&#xD;
&#xD;
          8. Stable analgesic regimen during the 4 weeks prior to enrollment.&#xD;
&#xD;
          9. Inadequate pain relief (minimum ≥50 mean on VAS with prior therapies lasting ≥3&#xD;
             months.&#xD;
&#xD;
         10. In the judgment of the Investigator, acceptable general medical condition&#xD;
&#xD;
         11. Male and female participants who are heterosexually active and not surgically sterile&#xD;
             or post-menopausal must agree to use effective contraception, including abstinence,&#xD;
             for the duration of the study and for 3 months after the study is completed&#xD;
&#xD;
         12. Have suitable facet joint anatomy for intra-articular injection&#xD;
&#xD;
         13. Willing and able to return for the follow-up (FU) visits&#xD;
&#xD;
         14. Able to reliably provide pain assessment (FAST test score R2≥0.7)&#xD;
&#xD;
         15. Able to read and understand study instructions, and willing and able to comply with&#xD;
             all study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity, allergy, or significant reaction to any ingredient of the study&#xD;
             drug, including double-stranded DNA, mannose, and sucrose&#xD;
&#xD;
          2. Scheduled surgical procedure or nerve ablation to joint within the next 6 months;&#xD;
             participant agrees not to schedule a surgical procedure, nerve ablation, or added&#xD;
             facet injection within 6 months of study treatment&#xD;
&#xD;
          3. High peri-operative risks which in the judgment of the investigator preclude a safe&#xD;
             facet joint injection procedure (e.g. extreme obesity putting injection accuracy at&#xD;
             risk, etc.)&#xD;
&#xD;
          4. Current treatment with immunosuppressive (systemic corticosteroid therapy [equivalent&#xD;
             to &gt;10mg/day prednisone] or other strong immunosuppressant)&#xD;
&#xD;
          5. History of immunosuppressive therapy; high-potency systemic steroids in the last 3&#xD;
             months.&#xD;
&#xD;
          6. Currently receiving systemic chemotherapy or radiation therapy for malignancy&#xD;
&#xD;
          7. Clinically significant hepatic disease as indicated by clinical laboratory results ≥3&#xD;
             times the upper limit of normal for any liver function test (e.g., aspartate&#xD;
             aminotransferase, alanine aminotransferase, lactate dehydrogenase)&#xD;
&#xD;
          8. Severe anemia (Grade 3; hemoglobin &lt;8.0 g/dL, &lt;4.9 mmol/L, &lt;80 g/L; transfusion&#xD;
             indicated), Grade 1 white cell counts (lymphocytes &lt;LLN - 800/mm3; &lt;LLN - 0.8 x 109&#xD;
             /L, neutrophils &lt;LLN - 1500/mm3; &lt;LLN - 1.5 x 109 /L)&#xD;
&#xD;
          9. Positive serology with reflex for human immunodeficiency virus, hepatitis B virus, or&#xD;
             hepatitis C virus within 4 weeks of commencing the study&#xD;
&#xD;
         10. Significant neuropsychiatric conditions; dementia, major depression, or altered mental&#xD;
             state that in the opinion of the Investigator will interfere with study participation&#xD;
&#xD;
         11. Current treatment with systemic antibiotics or antivirals (EXCEPTION: topical&#xD;
             treatments)&#xD;
&#xD;
         12. Current treatment with anticoagulants, other than low-dose aspirin&#xD;
&#xD;
         13. Known or suspected history of active alcohol or intravenous/oral drug abuse within 1&#xD;
             year before the screening visit&#xD;
&#xD;
         14. Use of any investigational drug or device within 1 month before enrollment or current&#xD;
             participation in a trial that included intervention with a drug or device; or&#xD;
             currently participating in an investigational drug or device study.&#xD;
&#xD;
         15. Any condition that, in the opinion of the Principal Investigator, could compromise the&#xD;
             safety of the participant, the participant's ability to communicate with the study&#xD;
             staff, or the quality of the data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Flavia Cicuttini, MD</last_name>
    <phone>+61 3 9903 0158</phone>
    <email>flavia.cicuttini@monash.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Cicuttini, MD</last_name>
      <phone>+61 3 9903 0158</phone>
      <email>flavia.cicuttini@monash.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anita Wluka, PhD, FRACP, MBBS</last_name>
      <phone>T: +61 3 9903 0994</phone>
      <email>anita.wluka@monash.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Flavia Cicuttini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gene therapy</keyword>
  <keyword>non-viral plasmid</keyword>
  <keyword>osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Spine</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not applicable. All patient records are de-identified</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

